Reducing the Toxicity of Designer Aminoglycosides as Nonsense Mutation Readthrough Agents for Therapeutic Targets.

A significant proportion of genetic disease cases arise from truncation of proteins caused by premature termination codons. In eukaryotic cells some aminoglycosides cause readthrough of premature termination codons during protein translation. Inducing readthrough of these codons can potentially be of therapeutic value in the treatment of numerous genetic diseases. A significant drawback to the repeated use of aminoglycosides as treatments is the lack of balance between their readthrough efficacy and toxicity. The synthesis and biological testing of designer aminoglycoside compounds is documented herein. We disclose the implementation of a strategy to reduce cellular toxicity and maintain readthrough activity of a library of compounds by modification of the overall cationic charge of the aminoglycoside scaffold through ring I modifications.

[1]  D. Crich,et al.  Synthesis of Gentamicin Minor Components: Gentamicin B1 and Gentamicin X2. , 2020, Organic letters.

[2]  Y. Yamanaka,et al.  The novel aminoglycoside, ELX-02, permits CTNSW138X translational read-through and restores lysosomal cystine efflux in cystinosis , 2019, PloS one.

[3]  M. Roberge,et al.  2-Aminothiazole-4-carboxamides Enhance Readthrough of Premature Termination Codons by Aminoglycosides. , 2019, ACS medicinal chemistry letters.

[4]  A. Ishiyama,et al.  Immunohistochemical localization of megalin and cubilin in the human inner ear , 2018, Brain Research.

[5]  S. Peltz,et al.  The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential , 2018, PloS one.

[6]  A. Vasella,et al.  Structure-Based Design and Synthesis of Apramycin-Paromomycin Analogues: Importance of the Configuration at the 6'-Position and Differences between the 6'-Amino and Hydroxy Series. , 2017, Journal of the American Chemical Society.

[7]  U. Wolfrum,et al.  Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs) , 2016, BioDrugs.

[8]  Narayana Murthy Sabbavarapu,et al.  Design of Novel Aminoglycoside Derivatives with Enhanced Suppression of Diseases-Causing Nonsense Mutations. , 2016, ACS medicinal chemistry letters.

[9]  Marina V. Rodnina,et al.  Structural basis for the inhibition of the eukaryotic ribosome , 2014, Nature.

[10]  M. Takano,et al.  Entry of aminoglycosides into renal tubular epithelial cells via endocytosis-dependent and endocytosis-independent pathways. , 2014, Biochemical pharmacology.

[11]  V. Belakhov,et al.  Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutations. , 2012, Journal of medicinal chemistry.

[12]  Jochen Schacht,et al.  New developments in aminoglycoside therapy and ototoxicity , 2011, Hearing Research.

[13]  V. Belakhov,et al.  Repairing faulty genes by aminoglycosides: Identification of new pharmacophore with enhanced suppression of disease-causing nonsense mutations , 2011 .

[14]  J. López-Novoa,et al.  An integrative overview on the mechanisms underlying the renal tubular cytotoxicity of gentamicin. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[15]  J. Rousset,et al.  Rescue of non-sense mutated p53 tumor suppressor gene by aminoglycosides , 2010, Nucleic acids research.

[16]  V. Belakhov,et al.  Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. , 2010, Bioorganic & medicinal chemistry.

[17]  J. Schacht,et al.  Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. , 2009, Journal of medicinal chemistry.

[18]  T. Ovesen,et al.  Cubilin and Megalin Co-Localize in the Neonatal Inner Ear , 2009, Audiology and Neurotology.

[19]  A. Mor,et al.  Structure-toxicity relationship of aminoglycosides: correlation of 2'-amine basicity with acute toxicity in pseudo-disaccharide scaffolds. , 2008, Bioorganic & medicinal chemistry.

[20]  Matthew Mort,et al.  A meta‐analysis of nonsense mutations causing human genetic disease , 2008, Human mutation.

[21]  T. Baasov,et al.  Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations. , 2006, Bioorganic & medicinal chemistry letters.

[22]  D. Bedwell,et al.  Pharmacological Suppression of Premature Stop Mutations that Cause Genetic Diseases , 2005 .

[23]  H. Chang,et al.  Tuning the regioselectivity of the Staudinger reaction for the facile synthesis of kanamycin and neomycin class antibiotics with N-1 modification. , 2005, Organic letters.

[24]  J. Wadhawan,et al.  Selective electrochemical glycosylation by reactivity tuning. , 2004, Organic & biomolecular chemistry.

[25]  J. Rousset,et al.  Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment , 2004, Gene Therapy.

[26]  M. Takano,et al.  Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. , 2004, Drug metabolism and pharmacokinetics.

[27]  Marvin J Miller,et al.  Total synthesis of desferrisalmycin B. , 2002, Journal of the American Chemical Society.

[28]  M. Evans,et al.  Aminoglycoside suppression of a premature stop mutation in a Cftr–/– mouse carrying a human CFTR-G542X transgene , 2002, Journal of Molecular Medicine.

[29]  J. Clancy,et al.  Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. , 2001, American journal of respiratory and critical care medicine.

[30]  Chi‐Huey Wong,et al.  Design and Synthesis of New Aminoglycoside Antibiotics Containing Neamine as an Optimal Core Structure: Correlation of Antibiotic Activity with in Vitro Inhibition of Translation , 1999 .

[31]  J. Puglisi,et al.  Structural origins of gentamicin antibiotic action , 1998, The EMBO journal.

[32]  H. Paulsen,et al.  Synthese der T-antigenen trisaccharide O-β-d-galactopyranosyl-(1→3)-O-(2-acetamido-2-desoxy-α-d-galactopyranosyl)-(1→6)-d-galactopyranose und O-β-d-galactopyranosyl-(1→3)-O-(2-acetamido-2-desoxy-α-d-galactopyranosyl)-(1→6)-d-glucopyranose und deren anknüpfung an proteine , 1983 .

[33]  E. Palmer,et al.  Mistranslation in a eucaryotic organism , 1978, Cell.